WeLinQ is a quantum computing solution interconnecting processors.
Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.
Operator of a regenerative medicine company intended to develop breast regeneration alternatives by 3D bioprinting. The company develops a bioprosthesis for breast reconstruction, enabling women to regain their self-confidence through natural products and get long-lasting and aesthetic results after the surgery.
Scintil Photonics SAS, founded in 2018 and based in Grenoble, France, specializes in the development of silicon photonic integrated circuits aimed at advancing high-speed optical communications and chip interconnections. The company offers a range of products, including multi-wavelength lasers, waveguides, wavelength filters, and photodetectors. By employing wafer-scale bonding techniques that combine Silicon and Indium Phosphide materials, Scintil Photonics creates fully integrated circuits that enhance performance and reliability while significantly lowering implementation costs. Their innovative approach allows for the monolithic integration of optical amplifiers and lasers on advanced silicon photonic circuits, making their solutions suitable for a variety of industrial applications.
Developer of a pacing device designed to maintain cardiac rhythm. The company's implanted leadless pacemakers incorporate a self-sustaining power patented technology harvesting the heart's kinetic energy and bringing disruptive technologies to conventional leadless pacemakers, enabling patients and healthcare professionals with cost-effective alternatives that will revolutionize patients' quality of life.
NaoX Technologies develops wireless headphones that listen to brain vibrations.
Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.
NAWATECHNOLOGIES, Société anonyme designs, develops, industrializes, and commercializes products based on organized nanostructures to enable improvements in materials and devices dedicated to energy, transportation, and environment markets. The company offers multifunctional materials and energy storage devices. NAWATECHNOLOGIES, Société anonyme was founded in 2013 and is based in Aix-en-Provence, France.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Quandela SAS, founded in 2017 and based in Palaiseau, France, specializes in the production of photonic and semiconductor chips designed for quantum computing applications. The company is recognized for its innovative product, E-delight, which serves as a solid-state source of single and highly indistinguishable photons. This technology plays a crucial role in advancing quantum photonics and quantum information research. Quandela's single-photon source device integrates photonics with semiconductor quantum dots, facilitating efficient collection of emitted single photons at high rates. This capability significantly reduces charge noise decoherence and enhances the emission of identical photons, which is vital for the development of advanced quantum technologies, including communication, computation, and sensing. By focusing on the unique properties of quantum light, Quandela contributes to the progress of photon-based quantum computing and communication networks.
Tallano Technologie is a French company founded in 2012, based in Boulogne-Billancourt, that specializes in reducing particle emissions from vehicle braking systems. The company has developed a proprietary technology known as tamic, which effectively captures particles at the source through suction. This innovative particle collector is designed to be installed between the brake disc and pad in both private cars and public transport vehicles. Tallano Technologie positions itself as a leader in the field of particle emission reduction, addressing environmental concerns associated with vehicular braking systems.
Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.
C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.
Adionics provides desalination supply chain. The company offers AquaOmnes, a technology that instead removes the salt out of salty water, leaving water behind; and Flionex, an ion-absorbing liquid technology that is used to bind salts. It serves municipal water, power, oil and gas, and chemicals markets. The company was founded in 2012 and is based in Paris, France.
Kyanos specializes in the production of microalgae-based food products, focusing on sustainability and environmental health. The company employs an innovative process for cultivating high-value polysaccharides and pigments using high-output micro-algae in vertical photo-reactors. This patented technology significantly enhances productivity while minimizing environmental impact. Kyanos aims to provide consumers with sustainable and contaminant-free food options, thereby contributing to a healthier planet and promoting eco-friendly dietary choices.
Antaios develops innovative memory technology. Antaios is fully engaged in bringing the technology to the market to help chip manufacturers solve the critical issue of exploding power requests in advanced semiconductor systems.
NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing. With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
GrAI Matter Labs utilizes biology-inspired spiking neural networks to overcome the limitations of traditional Von Neumann machines and application processors. Their massively parallel, fully programmable compute technology enables multi-modal sensor analytics and dynamic machine learning at low power levels not feasible before. Combining next generation neuromorphic compute with cutting edge silicon technologies brings AI to every edge device across the Internet of Things without the need for cloud computing support.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
SideROS, a biotechnology company, engages in research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells. It develops ironomycin, a chemical molecule, which disturbs iron homeostatis, involved in the maintenance of persister cancer cell, and provokes cell death by ferroptosis. The company was incorporated in 2019 and is based in Paris, France.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.
Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
NAWATECHNOLOGIES, Société anonyme designs, develops, industrializes, and commercializes products based on organized nanostructures to enable improvements in materials and devices dedicated to energy, transportation, and environment markets. The company offers multifunctional materials and energy storage devices. NAWATECHNOLOGIES, Société anonyme was founded in 2013 and is based in Aix-en-Provence, France.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.
Naïo Technologies SAS, founded in 2011 and based in Ramonville Saint Agne, France, specializes in designing and developing electric tools for agriculture and viticulture. The company focuses on creating robots that assist in mechanical weeding, hoeing, and harvesting, thereby improving farming efficiency and reducing reliance on chemical pesticides and herbicides. Through its innovative solutions, Naïo Technologies aims to help farmers optimize their workloads, enhance profitability, and minimize environmental impact. The firm’s commitment to integrating advanced technologies in agriculture highlights its role in promoting sustainable farming practices.
Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.
Scintil Photonics SAS, founded in 2018 and based in Grenoble, France, specializes in the development of silicon photonic integrated circuits aimed at advancing high-speed optical communications and chip interconnections. The company offers a range of products, including multi-wavelength lasers, waveguides, wavelength filters, and photodetectors. By employing wafer-scale bonding techniques that combine Silicon and Indium Phosphide materials, Scintil Photonics creates fully integrated circuits that enhance performance and reliability while significantly lowering implementation costs. Their innovative approach allows for the monolithic integration of optical amplifiers and lasers on advanced silicon photonic circuits, making their solutions suitable for a variety of industrial applications.
Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.
NH TherAguix SAS, a clinical stage pharmaceutical company, develops nanomedicines for cancer, combining imaging, and radiotherapy. It offers AGuIX, a nanoparticle that is designed to improve the localization of solid tumors and the outcomes of radiation therapy by intravenous injection; allows the radiation therapy treatment for patient to determine the optimal moment to perform the irradiation; and allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues. The company was founded in 2015 and is based in Villeurbanne, France.
Neurallys is a Paris-based company focused on the development and production of medical devices specifically for neurology and neurosurgery. The company is creating an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients suffering from hydrocephalus. This innovative device aims to enhance the efficiency of neurosurgeons in monitoring the condition, ultimately improving patient care and outcomes.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
NextMind SAS, established in 2017 and located in Paris, France, is a company focused on developing noninvasive brain-computer interface technology. Its innovative device utilizes neural signals from the brain, combined with machine learning algorithms, to allow users to control and navigate electronic devices, including computers, mobile devices, and virtual and augmented reality headsets, using only their thoughts. This technology translates neural signals into digital commands in real-time, enabling an immersive and intuitive user experience in gaming and other applications.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections.
Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
Neovacs S.A. is a biotechnology company based in Paris, France, that specializes in the development of therapeutic vaccines known as "Kinoids" for treating autoimmune, inflammatory diseases, allergies, and cancer. Founded in 1993 by Professor Daniel Zagury, the company aims to create innovative treatments that stimulate a natural polyclonal antibody response in patients, contrasting with traditional monoclonal antibody therapies. Neovacs' product pipeline includes IFNa Kinoid, which is undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, along with preclinical developments targeting diabetes. Additionally, the company is working on VEGF-Kinoid for age-related macular degeneration and solid tumors, and IL-4/IL-13 Kinoid for allergies. Neovacs also collaborates with the Sunnybrook Research Institute to advance preclinical research on VEGF-Kinoid for colorectal and ovarian cancer. The company holds a broad patent portfolio and is recognized as a pioneer in the field of therapeutic vaccines.
Geomnia possesses specific know-how and core skills in 3D metrology, software engineering, micro and nano-scale mecatronics metrology systems engineering, and process optimization by software and measuring.
Technogenia has specializes in tungsten carbide metallurgy, Anti-wear welding products and anti-wear coating with high-power laser.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.